Neurological Surgery 脳神経外科50巻2号

2022年03月発行

特集 水頭症—脳脊髄液動態への理解と治療に迫る Ⅱ特発性正常圧水頭症

特発性正常圧水頭症（iNPH）と鑑別すべき神経疾患

著者： 大道卓摩¹ 徳田隆彦²

所属機関： ¹京都府立医科大学脳神経内科 ²量子科学技術研究開発機構量子生命・医学部門量子医科学研究所脳機能イメージング研究部

ページ範囲：P.319 - P.330

Point
・アルツハイマー病と特発性正常圧水頭症（iNPH）の鑑別には，脳脊髄液リン酸化タウ濃度が有用である．
・パーキンソン病・レヴィ小体型認知症とiNPHの鑑別には，MIBG心筋シンチグラフィーが有用である．
・iNPHの鑑別疾患となり得る神経変性疾患は，iNPHと臨床診断できる症例に併存している場合もある．

参考文献

1）Kitagaki H, et al：CSF spaces in idiopathic normal pressure hydrocephalus：morphology and volumetry. AJNR Am J Neuroradiol 19：1277-1284, 1998

2）Alves J, et al：Posterior cortical atrophy and Alzheimer's disease：a meta-analytic review of neuropsychological and brain morphometry studies. Brain Imaging Behav 7：353-361, 2013

3）Teichmann M, et al：Deciphering logopenic primary progressive aphasia：a clinical, imaging and biomarker investigation. Brain 136：3474-3488, 2013

4）Ossenkoppele R, et al：The behavioural/dysexecutive variant of Alzheimer's disease：clinical, neuroimaging and pathological features. Brain 138：2732-2749, 2015

5）American Psychiatric Association：Diagnostic and Statical Manual of Mental Disorders, 5th edition. DSM-5. American Psychiatric Association Publishing, Arlington（VA）, 2013

6）McKhann GM, et al：The diagnosis of dementia due to Alzheimer's disease：recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7：263-269, 2011

7）Jack CR Jr, et al；Contributors：NIA-AA Research Framework：toward a biological definition of Alzheimer's disease. Alzheimers Dement 14：535-562, 2018

8）Bridel C, et al：Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology：a systematic review and meta-analysis. JAMA Neurol 76：1035-1048, 2019

9）Nakamura A, et al：High performance plasma amyloid-β biomarkers for Alzheimer's disease. Nature 554：249-254, 2018

10）Tatebe H, et al：Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology：pilot case-control studies including patients with Alzheimer's disease and down syndrome. Mol Neurodegener 12：63, 2017

11）Chen Z, et al：Cerebrospinal fluid Aβ42, t-tau, and p-tau levels in the differential diagnosis of idiopathic normal-pressure hydrocephalus：a systematic review and meta-analysis. Fluids Barriers CNS 14：13, 2017

12）Santangelo R, et al：Cerebrospinal fluid amyloid-β 42, total tau and phosphorylated tau are low in patients with normal pressure hydrocephalus：analogies and differences with Alzheimer's disease. J Alzheimers Dis 60：183-200, 2017

13）Jeppsson A, et al：CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics. J Neurol Neurosurg Psychiatry 90：1117-1123, 2019

14）Bech-Azeddine R, et al：Idiopathic normal-pressure hydrocephalus：clinical comorbidity correlated with cerebral biopsy findings and outcome of cerebrospinal fluid shunting. J Neurol Neurosurg Psychiatry 78：157-161, 2007

15）Cabral D, et al：Frequency of Alzheimer's disease pathology at autopsy in patients with clinical normal pressure hydrocephalus. Alzheimers Dement 7：509-513, 2011

16）Hamilton R, et al：Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology. Ann Neurol 68：535-540, 2010

17）Nakajima M, et al：Cerebrospinal fluid biomarkers for prognosis of long-term cognitive treatment outcomes in patients with idiopathic normal pressure hydrocephalus. J Neurol Sci 357：88-95, 2015

18）Pfanner T, et al：Cerebrospinal fluid biomarkers as predictors of shunt response in idiopathic normal pressure hydrocephalus：a systematic review. Can J Neurol Sci 45：3-10, 2018

19）Polymeropoulos MH, et al：Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276：2045-2047, 1997

20）Braak H, et al：Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24：197-211, 2003

21）Postuma RB, et al：MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 30：1591-1601, 2015

22）日本神経学会（監），「パーキンソン病診療ガイドライン」作成委員会（編）：パーキンソン病診療ガイドライン2018．医学書院，東京，2018

23）Stolze H, et al：Comparative analysis of the gait disorder of normal pressure hydrocephalus and Parkinson's disease. J Neurol Neurosurg Psychiatry 70：289-297, 2001

I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism：a systematic review and meta-analysis. Parkinsonism Relat Disord 18：494-500, 2012

25）Odagiri H, et al：Clinical characteristics of idiopathic normal pressure hydrocephalus with Lewy body diseases. J Neurol Sci 359：309-311, 2015

26）Sakurai A, et al：Comorbid alpha synucleinopathies in idiopathic normal pressure hydrocephalus. J Neurol, 2021　doi：10.1007/s00415-021-10778-1

27）Shahnawaz M, et al：Development of a biochemical diagnosis of Parkinson disease by detection of α-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol 74：163-172, 2017

28）Rossi M, et al：Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol 140：49-62, 2020

29）Kosaka K, et al：Presenile dementia with Alzheimer-, Pick- and Lewy-body changes. Acta Neuropathol 36：221-233, 1976

30）McKeith IG, et al：Diagnosis and management of dementia with Lewy bodies：Fourth consensus report of the DLB Consortium. Neurology 89：88-100, 2017

31）Hashimoto M, et al：Medial temporal and whole-brain atrophy in dementia with Lewy bodies：a volumetric MRI study. Neurology 51：357-362, 1998

32）Takahashi R, et al：Measurement of gray and white matter atrophy in dementia with Lewy bodies using diffeomorphic anatomic registration through exponentiated lie algebra：a comparison with conventional voxel-based morphometry. AJNR Am J Neuroradiol 31：1873-1878, 2010

33）Swift IJ, et al：Fluid biomarkers in frontotemporal dementia：past, present and future. J Neurol Neurosurg Psychiatry 92：204-215, 2021

34）Rascovsky K, et al：Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134：2456-2477, 2011

35）Gorno-Tempini ML, et al：Classification of primary progressive aphasia and its variants. Neurology 76：1006-1014, 2011

36）Whitwell JL, Josephs KA：Recent advances in the imaging of frontotemporal dementia. Curr Neurol Neurosci Rep 12：715-723, 2012

37）Ohmichi T, et al：Usefulness of the convexity apparent hyperperfusion sign in 123I-iodoamphetamine brain perfusion SPECT for the diagnosis of idiopathic normal pressure hydrocephalus. J Neurosurg 130：398-405, 2018

38）D'Alton S, Lewis J：Therapeutic and diagnostic challenges for frontotemporal dementia. Front Aging Neurosci 6：204, 2014

39）Steinacker P, et al：TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol 65：1481-1487, 2008

40）Kasai T, et al：Combined use of CSF NfL and CSF TDP-43 improves diagnostic performance in ALS. Ann Clin Transl Neurol 6：2489-2502, 2019

41）Wirth M, et al：Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline（SmartAge）-study protocol for a randomized controlled trial. Alzheimers Res Ther 11：36, 2019

42）Respondek G, et al；Movement Disorder Society-endorsed PSP Study Group：Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord 32：995-1005, 2017

43）Höglinger GU, et al；Movement Disorder Society-endorsed PSP Study Group：Clinical diagnosis of progressive supranuclear palsy：the movement disorder society criteria. Mov Disord 32：853-864, 2017

44）Steele JC, et al：Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 10：333-359, 1964

45）Ohara M, et al：Progressive supranuclear palsy often develops idiopathic normal pressure hydrocephalus-like magnetic resonance imaging features. Eur J Neurol 27：1930-1936, 2020

F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease：a multicenter study. Ann Neurol 82：622-634, 2017

47）Tagai K, et al：High-contrast in vivo imaging of tau pathologies in Alzheimer's and non-Alzheimer's disease tauopathies. Neuron 109：42-58.e8, 2021

F］THK-5351 in progressive supranuclear palsy. Eur J Neurol 24：130-136, 2017

49）Rebeiz JJ, et al：Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 18：20-33, 1968

50）Cordato NJ, et al：Corticobasal syndrome with tau pathology. Mov Disord 16：656-667, 2001

51）Boeve BF, et al：Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 54（Suppl 5）：S15-19, 2003

52）Ouchi H, et al：Pathology and sensitivity of current clinical criteria in corticobasal syndrome. Mov Disord 29：238-244, 2014

53）Alexander SK, et al：Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. J Neurol Neurosurg Psychiatry 85：925-929, 2014

54）Day GS, et al：Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. Neurology 88：1273-1281, 2017